133 related articles for article (PubMed ID: 15517916)
1. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma.
Effert P; Beniers AJ; Tamimi Y; Handt S; Jakse G
Anticancer Res; 2004; 24(5A):3057-63. PubMed ID: 15517916
[TBL] [Abstract][Full Text] [Related]
2. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues.
Binder C; Binder L; Marx D; Schauer A; Hiddemann W
Anticancer Res; 1997; 17(6D):4299-304. PubMed ID: 9494524
[TBL] [Abstract][Full Text] [Related]
3. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
4. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.
Chandler JD; Williams ED; Slavin JL; Best JD; Rogers S
Cancer; 2003 Apr; 97(8):2035-42. PubMed ID: 12673735
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
6. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture.
Aloj L; Caracó C; Jagoda E; Eckelman WC; Neumann RD
Cancer Res; 1999 Sep; 59(18):4709-14. PubMed ID: 10493529
[TBL] [Abstract][Full Text] [Related]
7. The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells.
Pissimissis N; Papageorgiou E; Lembessis P; Armakolas A; Koutsilieris M
Anticancer Res; 2009 Jan; 29(1):371-7. PubMed ID: 19331175
[TBL] [Abstract][Full Text] [Related]
8. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.
Cantuaria G; Magalhaes A; Penalver M; Angioli R; Braunschweiger P; Gomez-Marin O; Kanhoush R; Gomez-Fernandez C; Nadji M
Gynecol Oncol; 2000 Oct; 79(1):33-7. PubMed ID: 11006027
[TBL] [Abstract][Full Text] [Related]
9. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.
Reinicke K; Sotomayor P; Cisterna P; Delgado C; Nualart F; Godoy A
J Cell Biochem; 2012 Feb; 113(2):553-62. PubMed ID: 21938742
[TBL] [Abstract][Full Text] [Related]
10. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
11. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Vaday GG; Peehl DM; Kadam PA; Lawrence DM
Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
[TBL] [Abstract][Full Text] [Related]
12. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines.
Dizeyi N; Bjartell A; Hedlund P; Taskén KA; Gadaleanu V; Abrahamsson PA
Eur Urol; 2005 Jun; 47(6):895-900. PubMed ID: 15925089
[TBL] [Abstract][Full Text] [Related]
13. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
15. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
16. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
Meyer-Siegler KL; Iczkowski KA; Vera PL
BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
[TBL] [Abstract][Full Text] [Related]
17. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.
Alimirah F; Chen J; Basrawala Z; Xin H; Choubey D
FEBS Lett; 2006 Apr; 580(9):2294-300. PubMed ID: 16580667
[TBL] [Abstract][Full Text] [Related]
18. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
19. ILK as a potential marker gene to ascertain specific adenocarcinoma cell mRNA isolation from frozen prostate biopsy tissue sections.
Kieffer N; Schmitz M; Plançon S; Margue C; Huselstein F; Grignard G; Dippel W; Nathan M; Giacchi S; Scheiden R
Int J Oncol; 2005 Jun; 26(6):1549-58. PubMed ID: 15870868
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Res Commun Mol Pathol Pharmacol; 2004; 115-116():251-64. PubMed ID: 17564322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
